ELREXFIO authorized by Health Canada for adults with relapsed in Canada

eAwazMedicine

KIRKLAND – Pfizer Canada announced that Health Canada has granted a Notice of Compliance with conditions (NOC/c) to ELREXFIO (elranatamab solution for injection). ELREXFIO is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, …

Janssen Seeks FDA Approval for CARVYKTI

eAwazMedicine

London – Application is supported by data from the Phase 3 CARTITUDE-4 study, which showed significant improvement in primary endpoint of progression-free survival (PFS) CARTITUDE-4 is the first randomized Phase 3 study investigating the efficacy of a cell therapy as early as after first relapse in multiple myeloma RARITAN, N.J., June 6, 2023 – The Janssen Pharmaceutical Companies of Johnson …